journal article·2020-01-01Open access

RDM1 plays an oncogenic role in human ovarian carcinoma cells

Lu Tong, Wenjiao Cao, Jun Sheng, Enhao Zhu, Ying Yu, Tianying Zhong, Yajun Chen, Lihua Wang

Abstract

Ovarian cancer is one of the deadliest gynecological cancer, with a low overall 5-year survival rate. RDM1, RAD52 motif-containing protein 1, is sensitive to cisplatin, a common chemotherapy drug and it has an important role inDNA damage repair pathway. Until now, the effect of RDM1 in ovarian cancer is undiscovered. Here, clinical data shows that the tumour tissues of ovarian carcinoma patients with higher mRNA and protein expression of RDM1. Knockdown of RDM1 in ovarian carcinoma cells reduces cell proliferation and promotes apoptosis, consistent with the role RDM1 in the overexpression experiments. The research of xenograft mouse model shows stable knockdown of RDM1 significantly inhibits ovarian cancer tumour growth. These in vitro and in vivo results conclude that RDM1 plays an oncogenic role in human ovarian carcinoma. Interestingly, p53/RAD51/RAD52 signalling pathway can be regulated by RDM1, and the negative regulation of p53 by RDM1 may be one of major mechanisms for RDM1 to accomplish its oncogenic functions in ovarian carcinoma. Therefore, RDM1 may be a new target for the treatment of ovarian carcinoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: DNA Repair Mechanisms · Cancer-related Molecular Pathways · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, The China Welfare Institute

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University

Department of Orthopedics, the General Hospital of Western Theater Command

Department of Clinical Laboratory, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital

Funding

National Natural Science Foundation of China · Shanghai Collaborative Innovation Centre for Translational Medicine · Shanghai Municipal Key Clinical Specialty · China Postdoctoral Science Foundation · Foundation of Science Technology Department of Sichuan Province

References (18)

Show source-provided references
1. 10.3322/caac.2116610.3322/caac.21166 ↗
2. 10.7150/jca.781010.7150/jca.7810 ↗
3. 10.1186/s12967-014-0271-510.1186/s12967-014-0271-5 ↗
4. 10.1158/1078-0432.CCR-17-370210.1158/1078-0432.CCR-17-3702 ↗
5. van den Bosch M, Lohman PH, Pastink A. DNA double-strand break repair by homologous recombination. Biol. Chem. 2002;383(6):873–892.
6. 10.1038/nrm112710.1038/nrm1127 ↗
7. 10.1093/nar/gkm75310.1093/nar/gkm753 ↗
8. 10.1074/jbc.M41287420010.1074/jbc.M412874200 ↗
9. 10.1186/1471-2407-12-7510.1186/1471-2407-12-75 ↗
10. 10.1038/ncomms787510.1038/ncomms7875 ↗
11. 10.1530/EC-17-020910.1530/EC-17-0209 ↗
12. 10.1038/s41598-018-30071-y10.1038/s41598-018-30071-y ↗
13. 10.1111/jcmm.1442510.1111/jcmm.14425 ↗
14. 10.1074/jbc.M20651120010.1074/jbc.M206511200 ↗
15. 10.4161/cc.5.10.276410.4161/cc.5.10.2764 ↗
16. 10.1016/j.dnarep.2004.03.02710.1016/j.dnarep.2004.03.027 ↗
17. 10.1016/j.molcel.2010.09.01910.1016/j.molcel.2010.09.019 ↗
18. 10.1016/j.molcel.2007.11.01510.1016/j.molcel.2007.11.015 ↗